Patents by Inventor David Porubek
David Porubek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060211713Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: ApplicationFiled: March 8, 2006Publication date: September 21, 2006Inventors: David Porubek, Anil Kumar, Charles Bredl, J. Klein
-
Patent number: 7053096Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: GrantFiled: May 5, 2004Date of Patent: May 30, 2006Assignee: Cell Therapeutics Inc.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Publication number: 20040229836Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: ApplicationFiled: May 5, 2004Publication date: November 18, 2004Applicant: CELL THERAPEUTICS, INC.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Patent number: 6780865Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: GrantFiled: September 18, 1997Date of Patent: August 24, 2004Assignee: Cell Therapeutics, Inc.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Patent number: 6693105Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.Type: GrantFiled: July 27, 1999Date of Patent: February 17, 2004Assignee: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
-
Publication number: 20030207901Abstract: Disclosed are therapeutic compounds having the formula:Type: ApplicationFiled: May 14, 2003Publication date: November 6, 2003Applicant: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
-
Patent number: 6133274Abstract: Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.Type: GrantFiled: November 26, 1996Date of Patent: October 17, 2000Assignee: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
-
Patent number: 5965564Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: March 20, 1998Date of Patent: October 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5804584Abstract: Disclosed are therapeutic compounds having the formula:(R)j-(core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.Type: GrantFiled: June 6, 1995Date of Patent: September 8, 1998Assignee: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
-
Patent number: 5792772Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: August 11, 1998Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5780476Abstract: Disclosed are therapeutic compounds having the formula:(R)j - (core moiety),including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non-cyclic or comprises at least one five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C.sub.1-6 alkyl or C.sub.1-6 alkenyl, and at least one R has the formula I: ##STR1## n is an integer from seven to twenty and at least one of X or Y is --OH. The other of X or Y, which is not --OH, is hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --, and each W.sub.1, W.sub.2, and W.sub.3 is independently hydrogen, CH.sub.3 --, CH.sub.3 --CH.sub.2 --, CH.sub.3 --(CH.sub.2).sub.2 -- or (CH.sub.3).sub.2 --CH.sub.2 --. The X, Y, W.sub.1, W.sub.2, or W.sub.Type: GrantFiled: June 6, 1995Date of Patent: July 14, 1998Assignee: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson
-
Patent number: 5739138Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: April 14, 1998Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5648357Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: September 16, 1994Date of Patent: July 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5629315Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: May 13, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5621102Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: April 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5620984Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating inflammatory disease.Type: GrantFiled: June 1, 1995Date of Patent: April 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5612349Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: March 18, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5580873Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating proliferative vascular disease.Type: GrantFiled: June 1, 1995Date of Patent: December 3, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5580874Abstract: Them is disclosed compounds and pharmaceutical compositions that is R enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating the side effects of immunosuppressive agent and interleukin-2 therapy.Type: GrantFiled: June 1, 1995Date of Patent: December 3, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5567704Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating baldness.Type: GrantFiled: June 1, 1995Date of Patent: October 22, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer